NASDAQ:KLRS Kalaris Therapeutics (KLRS) Stock Price, News & Analysis $3.56 +0.48 (+15.58%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock About Kalaris Therapeutics Stock (NASDAQ:KLRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kalaris Therapeutics alerts:Sign Up Key Stats Today's Range$3.08▼$3.9650-Day Range$2.27▼$3.0852-Week Range$2.14▼$24.15Volume328,105 shsAverage Volume45,653 shsMarket Capitalization$66.57 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Read More Kalaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreKLRS MarketRank™: Kalaris Therapeutics scored higher than 10% of companies evaluated by MarketBeat, and ranked 916th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingKalaris Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKalaris Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Kalaris Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioKalaris Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for KLRS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKalaris Therapeutics does not currently pay a dividend.Dividend GrowthKalaris Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for KLRS. News and Social Media2.6 / 5News SentimentN/A News SentimentKalaris Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kalaris Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for KLRS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kalaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders74.99% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kalaris Therapeutics' insider trading history. Receive KLRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLRS Stock News HeadlinesLeerink Partnrs Issues Negative Forecast for KLRS EarningsAugust 19, 2025 | americanbankingnews.comWhat is William Blair's Forecast for KLRS Q3 Earnings?August 18, 2025 | americanbankingnews.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 28 at 2:00 AM | Investors Alley (Ad)Kalaris Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 13, 2025 | globenewswire.comBernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. SecuritiesJune 5, 2025 | globenewswire.comKalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity ConferenceJune 2, 2025 | globenewswire.comSee More Headlines KLRS Stock Analysis - Frequently Asked Questions How have KLRS shares performed this year? Kalaris Therapeutics' stock was trading at $2.79 at the start of the year. Since then, KLRS shares have increased by 27.6% and is now trading at $3.56. How were Kalaris Therapeutics' earnings last quarter? Kalaris Therapeutics Inc. (NASDAQ:KLRS) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.10. Who are Kalaris Therapeutics' major shareholders? Top institutional investors of Kalaris Therapeutics include Octagon Capital Advisors LP (1.93%), Gilead Sciences Inc. (1.70%) and XTX Topco Ltd (0.13%). How do I buy shares of Kalaris Therapeutics? Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2025Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KLRS CIK1754068 WebN/A Phone(617) 433-2605FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Kalaris Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside-15.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.02% Return on Assets-65.15% Debt Debt-to-Equity RatioN/A Current Ratio11.98 Quick Ratio11.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book1.25Miscellaneous Outstanding Shares18,700,000Free Float4,677,000Market Cap$66.57 million OptionableN/A Beta0.49 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:KLRS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.